The discovery of JAK2 mutation 1 (JAK2V617F) has led to the proposal of new algorithms to diagnose and classify Ph-negative myeloproliferative disorders (MPDs). 2 Separation of polycythemia vera (PV) from essential thrombocythemia (ET) could become less clear, especially in JAK2V617F patients, if one considers that mutated PV and ET are similar conditions. 3, 4 Yet, no prospective data support this assumption. In particular, both the short-term risk of thrombosis and long-term risk of evolution to leukemia have not been shown to be similar in JAK2-mutated ET and PV. 3 The main biological difference between PV and ET lies in absolute erythrocytosis, formally demonstrated by red cell mass (RCM) measurement. The current WHO criteria for PV diagnosis require either increased RCM above 125% of predicted value or hemoglobin (Hb) level above 18.5 g/dl in men and 16.5 g/dl in women. In addition, some investigators have suggested setting a threshold for hematocrit (Ht) at 52% in men and 48% in women to diagnose PV in JAK2-mutated patients. 5 In contrast, diagnosis of ET requires excluding PV. Using Hb or Ht values for this purpose could avoid RCM measurement if those parameters were reliable for detecting erythrocytosis in MPD. 2, 6 This study aimed to evaluate the prevalence and prognostic impact of erythrocytosis in MPD patients classified as ET on peripheral blood counts, by reviewing all patients referred to two nuclear medicine departments for RCM determination between 1996 and 2006. Of 566 patients tested (after eliminating causes of reactive thrombocytosis), 71 had thrombocytosis and Hb and Ht below the values used for PV diagnosis (as defined above), and were therefore diagnosed with ET before RCM measurement.
RCM was normal in 38 of those 71 patients, but was higher than 125% of the predicted value, therefore revealing inapparent erythrocytosis, in the 33 remaining cases. Thus, after RCM measurement, final diagnosis was ET in 53.5% (38/71) and PV in 46.5% (33/71) of the patients, respectively. In addition to significantly higher Ht, patients with elevated RCM were more frequently males, had lower platelet counts (P ¼ 0.012) and higher leukocyte counts (P ¼ 0.041) ( Table 1 ). Serum erythropoietin (EPO) level and presence of endogenous erythroid (EEC) and/or megakaryocytic colonies did not significantly differ between the two groups. JAK2 mutational status was available in 49 of the 71 patients, and JAK2V617F mutation was found in 28 of them (57.1%), a proportion similar to that usually reported in ET patients. However, JAK2V617F was found in 10 of the 28 (35.7%) patients with normal RCM (reclassified as ET) and in 18 of the 21 patients (85.7%) with increased RCM (reclassified as PV) (P ¼ 0.0005; Table 1 ). Those results confirm the strong correlation between the presence of JAK2 mutation and erythrocytosis. Such findings may also explain the important rate of phenotypic evolution from ET to PV reported in JAK2-mutated patients, methodical measurement of RCM in this series permitting earlier detection of erythrocytosis.
Therefore, in this series of MPD with isolated thrombocytosis, 46.5% would have been misdiagnosed as ET instead of PV in the absence of RCM measurement, this proportion reaching 64.3% in JAK2-mutated patients. Other markers of PV, such as low serum EPO level and EEC formation, could not distinguish between patients with and without erythrocytosis ( Table 1 ). In contrast, absolute erythrocytosis was found in only 3 of 21 patients without JAK2 mutation, suggesting that RCM measurement is probably not necessary in JAK2-negative patients with isolated thrombocytosis in clinical practice. Such cases (JAK2V617F-negative patients with thrombocytosis and erythrocytosis) however may be important to identify for research purposes, as they possibly indicate a population where other mutations could be found.
Making a diagnosis of PV versus ET in this situation may have clinical relevance and a therapeutic impact. Indeed, in this study, PV patients presenting with isolated thrombocytosis tended to have higher rate of thrombosis (39.4%) and three progressed to myelofibrosis, including subsequent progression to acute leukemia in one, compared with 21% thrombotic events and absence of hematological evolution in the ET group after comparable median follow-up (40.4 and 42.3 months in PV and ET, respectively), even if differences were not significant (Table 1) . Comparing the risk of thrombosis according to JAK2 mutational status instead of RCM value, we found a similar trend to higher rate of thrombosis in patients with JAK mutation compared to those without JAK2 mutation (36 and 24%, respectively), but this difference was not significant (P ¼ 0.53).
ET is now clearly considered a heterogeneous disease. For example, some patients clinically diagnosed as ET have 8 This study shows that another proportion of ET patients have early-stage polycythemia when RCM is systematically measured. Polycythemia was mainly but not only found in patients with JAK2 mutation, and its presence tended to predict a higher risk of thrombosis and of hematological transformation, which will have to be confirmed on larger numbers of patients. Therefore, our results suggest that, at least in cases presenting with isolated thrombocytosis, RCM measurement is useful for proper MPD classification and management until prospective data support the proposal of a molecular instead of 'clinical' classification of Ph-negative MPD. 1 BCR-ABL-negative chronic myeloproliferative diseases (CMPD) and myelodysplastic syndromes (MDS) are both very heterogeneous and in some cases show cytomorphological and clinical overlaps. This is especially true for the subentities chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia and myelodysplastic/myeloproliferative disease, unclassifiable', which were classified by the WHO as its own category of myelodysplastic/myeloproliferative disorders. Recently, refractory anemia with ringed sideroblasts associated with anemia but marked thrombocytosis 4500 Â 10 9 /l, and a proportion of at least 15% of ringed sideroblasts in the bone marrow was added as a distinct entity to this category. [1] [2] [3] [4] [5] Most cases of RARS-T show a normal karyotype. [1] [2] [3] [4] [5] In addition, this specific subtype was reported to have a high frequency of the JAK2 V617F mutation. 1, 2, 4 The V617F mutation is primarily associated with the CMPD, being found in nearly all polycythemia vera (PV) and in 50-60% of all essential thrombocytosis (ET) and chronic idiopathic myelofibrosis (CIMF) cases, but was also detected rarely in MDS. 6 Therefore, the high frequency of JAK2 V617F in RARS-T emphasizes the ambiguous position of this subentity between CMPD and MDS, as do molecular and cytomorphological aspects. However, the genetic characterization of RARS-T is not complete, as 10-50% of all cases did not show a V617F mutation.
Lately, somatic mutations of the MPL gene with its coding function for the thrombopoietin receptor were detected in B5% of CIMF and in B1% of all ET. So far, two different variants, the W515L and the W515K mutation, were identified. They are localized in the transmembranous domain and thus might be critical for receptor dimerization. They cause single amino-acid exchanges (tryptophan to leucine or lysine, respectively) and confer constitutive cytokine-independent activation of the JAK-STAT pathway as gain-of-function mutations, similar to the V617F. 7, 8 So far, they were not detected in PV, AML, MDS or CMML. 7 Here we report on the detection of an MPLW515 exchange in a patient with clinical and cytomorphological features not only of an ET but also of RARS-T who was negative for the JAK2 V617F mutation. This is, to our knowledge, the first description of an MPLW515 mutation in such an overlapping disease with difficult differential diagnosis.
A 63-year-old male patient showed incidentally marked thrombocytosis (1.222 Â 10 9 G/l; WBC 6.4 Â 10 9 G/l, Hb 133 g/l). He was in good physical condition and did not suffer from any clinical symptoms. There was no organomegaly at clinical examination. Past history revealed no abnormalities. Owing to the isolated thrombocytosis, a diagnosis of ET was suspected. Bone marrow cytomorphology showed normal cellularity and a strongly increased megakaryopoiesis. Granulopoiesis showed normal features, and bone marrow blasts were o5%. Erythropoiesis was slightly increased to 45% of nucleated cells in the bone marrow and showed signs of dysplasia in 410% of cells.
